Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains
about
Oestrogen (adjunct) versus placebo for women with schizophreniaTreating Negative Symptoms in Schizophrenia: an UpdateOmega 3 Fatty Acids: Novel Neurotherapeutic Targets for Cognitive Dysfunction in Mood Disorders and Schizophrenia?Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewNegative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotionEffects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic MiceStem cell-derived interneuron transplants as a treatment for schizophrenia: preclinical validation in a rodent modelRecommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.Cortical PGC-1α-Dependent Transcripts Are Reduced in Postmortem Tissue From Patients With SchizophreniaDifferential Effects of Olanzapine and Haloperidol on MK-801-induced Memory Impairment in MiceA phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.Abnormal context-reward associations in an immune-mediated neurodevelopmental mouse model with relevance to schizophrenia.Mechanisms of NOS1AP action on NMDA receptor-nNOS signaling.Investigational drugs for anxiety in patients with schizophrenia.Lurasidone in the treatment of schizophrenia: a critical evaluation.Potential serotonergic agents for the treatment of schizophrenia.Cognitive impairment in schizophrenia: the great unmet need.Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.2-methoxyestradiol impacts on amino acids-mediated metabolic reprogramming in osteosarcoma cells by its interaction with NMDA receptor.Cell-based therapies for the treatment of schizophrenia.Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?Risperidone improves interpersonal perception and executive function in patients with schizophrenia.Development of CNS multi-receptor ligands: Modification of known D2 pharmacophoresAlpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled TrialsSchizophrenia therapy options increasing.Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine.d-Serine administration affects nitric oxide synthase 1 adaptor protein and DISC1 expression in sex-specific manner.Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
P2860
Q26471707-E5D0F6A0-E706-4C00-B2C5-C70C0D49103FQ26744805-94B23280-6FC3-4341-BE1B-7F7A803CA5ACQ26782982-BA9F4550-40F9-4562-BFB9-FE9D88A64287Q26782993-06098F97-F477-47F3-B1A3-2ADDF31462F8Q27325106-1B3D0556-AB80-4322-9793-3B2B406F620AQ30364693-2A2F86B6-9195-4417-A0C9-69C13CD7F56EQ30837351-EBADC721-D994-4C98-BCBE-70F4F121AD34Q35984960-BB8DA8F2-4E9B-45BA-960F-423D25EC997AQ36371727-7671008D-0693-4960-9F49-D76518056470Q36994831-BC668E7B-B731-4664-89BB-1F33B95F3F52Q37160637-E083DE3E-532B-4698-9E04-D12434E44AE4Q37338780-6008039E-5AF4-46DA-A685-6E3D94FE8C6DQ37347747-0C54010F-02A3-4E0B-8A18-DD7F117142F4Q38249173-2BDEA04A-4397-4C1A-AF88-D30D369E23B6Q38271298-DFFF67E1-2603-4B01-A3A1-08E55C7A6107Q38537910-09E49DAD-D1D5-44A5-A417-4491C7230B94Q38635792-A964C5D5-E436-4A40-A1AC-C03F537ACF5FQ38673548-DF73807F-F095-435D-BD37-87E580226F69Q38718345-76161DF6-FC79-4C9C-8C71-3CC2B15F5FC9Q38927564-A8DB7D59-5A7F-4303-908F-E2EC729A70F2Q38932809-AE24A2B0-0440-4F02-B8EB-2D4EC4EC7936Q39065466-4E220D7F-533E-4A7D-9ECE-9127C8050DB9Q40571141-AD3340C5-032B-432C-AC24-560AA71AFB22Q40626733-C1FC32CA-C342-444D-AF60-BADE6A8DB1FFQ41687338-35E6B7A2-58F7-4791-8D54-CF8BFE70491CQ42870732-6966B5DC-043A-41E5-BC1C-815965516B3FQ50488312-6F5CF482-61EF-417E-ABCB-11BCD9B929CDQ51730519-3E29F595-057F-48B8-AAF0-D2C33CEAFB90Q57483192-C5A595F8-16F1-4132-B699-660E25E6AE62
P2860
Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Unmet needs in the treatment o ...... help different symptom domains
@ast
Unmet needs in the treatment o ...... help different symptom domains
@en
Unmet needs in the treatment o ...... help different symptom domains
@nl
type
label
Unmet needs in the treatment o ...... help different symptom domains
@ast
Unmet needs in the treatment o ...... help different symptom domains
@en
Unmet needs in the treatment o ...... help different symptom domains
@nl
prefLabel
Unmet needs in the treatment o ...... help different symptom domains
@ast
Unmet needs in the treatment o ...... help different symptom domains
@en
Unmet needs in the treatment o ...... help different symptom domains
@nl
P3181
P356
P1476
Unmet needs in the treatment o ...... help different symptom domains
@en
P3181
P356
10.4088/JCP.13049SU1C.04
P407
P478
75 Suppl 1
P577
2014-01-01T00:00:00Z